Immediately prior to the SPC session, rats were randomly allocated to receive an injection of either saline (Group VEH), one of three doses of the D1R antagonist SCH39166 (Groups SCH-Low, SCH-Mid and SCH-High), or one of three doses of the D2R antagonist eticlopride (ETI-Low, ETI-Mid, or ETI-High). The gene discussed is DRD1; the disease is spindle cell hemangioma.